October 7, 2025 — Leads & Copy — Positive results from the Bax24 Phase III trial reveal that baxdrostat significantly reduced ambulatory 24-hour average systolic blood pressure (SBP) compared to placebo at 12 weeks. The drug was generally well tolerated, with a safety profile consistent with the BaxHTN trial.
Baxdrostat, administered at 2mg, demonstrated efficacy throughout the 24-hour period, including early morning, for patients with treatment-resistant hypertension (rHTN).
Dr. Bryan Williams, primary investigator and Chair of Medicine at University College London, stated the results are groundbreaking and could change the treatment approach for uncontrolled hypertension patients.
Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, mentioned the company is advancing regulatory filings and clinical development for baxdrostat as a mono- and combination-therapy for conditions where aldosterone plays a key role.
The data will be shared with regulatory authorities and presented at the American Heart Association (AHA) Scientific Sessions in November 2025.
Baxdrostat is designed to lower blood pressure by inhibiting aldosterone. It is being investigated as a monotherapy for hypertension and primary aldosteronism, and in combination with dapagliflozin for chronic kidney disease and heart failure prevention.
Contact: Investor Relations – AstraZeneca, Media Relations – AstraZeneca
Source: AstraZeneca
